29 results about "Carbohydrate antigen" patented technology

The invention belongs to the technical field of antibody preparation, and particularly relates to an anti-human carbohydrate antigen CA125 monoclonal antibody and application thereof. The amino acid sequences of CDR1-3 on a light chain variable region of the monoclonal antibody are respectively shown as SEQ ID NO.3-5, and the amino acid sequences of CDR1-3 on a heavy chain variable region of the monoclonal antibody are respectively shown as SEQ ID NO.8-10. The monoclonal antibody provided by the invention can specifically recognize and bind to a natural carbohydrate antigen CA125 expressed by human cells or tissues, has good affinity and relatively high sensitivity of binding of the antibody and the antigen, has strong anti-interference ability to complex non-target protein components in the cells / tissues, is beneficial to significantly improving the accuracy and reliability of immunodetection of human CA125 protein, and has good application prospects. The method is suitable for high-specificity, high-sensitivity and high-reliability detection of the human CA125 protein, and has good applicability in a plurality of detection systems such as immunoblotting, immunoprecipitation, immunohistochemistry and the like.

The invention relates to the technical field of albumin oligopeptides, in particular to a preparation method of albumin oligopeptides and application of the albumin oligopeptides in promotion of postoperative patient recovery. The albumin oligopeptide provided by the invention can be taken before, during or after an operation, not only can quickly promote postoperative recovery and reduce the content of total bilirubin and direct bilirubin of a patient, but also can reduce the activity of glutamic oxalacetic transaminase and glutamic-pyruvic transaminase, and also can reduce the activity of carbohydrate antigen 199 and the content of alpha fetoprotein. In addition, by taking the albumin oligopeptide, the bitter throat dryness can be improved, nausea and vomiting symptoms can be eliminated, and the albumin oligopeptide has the effect of promoting postoperative liver function recovery of obstructive jaundice.

The present invention relates to a cancer vaccine conjugate comprising a CRM197 carrier protein and an immunogenic peptide covalently linked to the residues C186 and 0201 of the CRM197 carrier by means of a linker. Suitable immunogenic peptides include glycopeptides, such as glycopeptides comprising a tumor associated carbohydrate antigen (TACA) (e.g., GalNAc, Galb (1, 3) GalNAc or Neu5Ac alpha (2-6) GalNAc). Cancer vaccine conjugates, methods of producing and uses thereof are provided.

The present application relates to the field of chemiluminescent immunoassay, and specifically to water-soluble acridine sulfonamide derivatives, preparation methods, applications thereof, and kits. In some embodiments, the water-soluble acridine sulfonamide derivatives can label sulfhydryl groups under weakly alkaline or acidic conditions and are water-soluble, thereby being applicable to carbohydrate antigen detection.

The invention belongs to the technical field of quality control products of tumor markers such as carbohydrate antigens, and particularly relates to a liquid quality control product of tumor markers containing multiple carbohydrate antigens, which takes human serum as a matrix and comprises the following components: A, non-analytes including blocking proteins, B, non-analytes including C and D; the blocker is a functional protein obtained by modifying a blocker through fucosylation, and a fucose-containing sugar chain structure is introduced through enzymolysis and glycosylation, so that the blocker can specifically recognize a fucose-containing Si-Lea epitope shared by carbohydrate antigens; the B analyte comprises carbohydrate antigens and other markers, and the other markers comprise tumor markers and non-tumor related markers. Aiming at the problems of obvious cross reaction of carbohydrate antigens and insufficient stability of liquid quality control products, the invention provides a multi-component synergistic system taking blocker protein as a core, and high uniformity, stability and detection convenience of the liquid quality control products are realized by specifically combining carbohydrate antigen conserved epitopes and dynamically blocking the cross reaction.

The invention relates to the technical field of immunosensors, in particular to a Gd MOF composite material, an immunosensor and a preparation method and application of the immunosensor. The preparation method of the Gd MOF composite material comprises the following steps: dissolving polyether F127 in a mixed solvent, then adding gadolinium (Gd) salt and 5-aminoisophthalic acid (5-AIPA), and carrying out a first heating reaction to obtain Gd MOF; and dispersing the Gd MOF in a copper salt solution, and carrying out a second heating reaction to obtain the Gd MOF composite material. The invention also provides the double-ligand Gd MOF composite material prepared by adopting the method, an antibody-combined illuminant, an immunosensor and a preparation method of the double-ligand Gd MOF composite material. The invention provides a novel MOF material which is used for an ECL sensing system, and efficient detection of carbohydrate antigen 19-9 (CA19-9) is achieved.

The invention relates to the technical field of medical diagnosis and artificial intelligence aided decision making, and discloses a pancreatic cancer early screening method for people with new diabetes mellitus based on MUC2 pancreatic cancer cell exosome ACOT7. Detecting expression levels of three biomarkers, namely ACOT7 protein, MUC2 protein and serum carbohydrate antigen CA19-9, derived from pancreatic cancer cell exosomes in blood, inputting a pancreatic cancer risk assessment model based on a three-level sequential feature refining architecture, and outputting an integrated risk likelihood ratio; and finally generating a structured screening report containing hierarchical risk decision categories and clinical suggestions. According to the method, accurate, efficient and automatic early risk stratification of high-risk groups suffering from the pancreatic cancer with new diabetes mellitus is realized, and the early detection rate of the pancreatic cancer is remarkably improved.

The present invention belongs to the technical field of quality control products containing tumor markers such as carbohydrate antigens, and specifically relates to a liquid quality control product for tumor markers containing multiple carbohydrate antigens. The liquid quality control product uses human serum as a matrix and contains the following components: A non-analyte includes blocking protein, which is a functional protein modified by fucosylation of the blocking agent. The sugar chain structure containing fucose is introduced through enzymatic hydrolysis and glycosylation, so that it can specifically recognize the fucose-containing Si-Lea epitope shared by carbohydrate antigens; B analytes include carbohydrate antigens and other markers, and other markers include tumor markers and non-tumor-related markers. In response to the problems of significant cross-reaction of carbohydrate antigens and insufficient stability of liquid quality control products, the present invention provides a multi-component synergistic system with blocking protein as the core. By specifically binding to the conserved epitopes of carbohydrate antigens and dynamically blocking cross-reactions, high uniformity, stability and convenient detection of liquid quality control products are achieved.

The present invention relates to humanized anti-Lewis Y antibodies that specifically bind Lewis Y and do not show any cross-reactivity. In particular, the humanized anti-Lewis Y antibodies do not bind to Lewis b or any other blood group carbohydrate antigen. In particular, the present invention relates to humanized anti-Lewis Y antibodies for use in the treatment of cancer.

This invention relates to the field of biotechnology, and more particularly to a biomarker, kit, and application for the diagnosis of pancreatic malignant tumors. The biomarker comprises aldehyde-ketone reductase 1B10 protein and carbohydrate antigen 19-9 protein. This biomarker is a secreted serum protein that can specifically distinguish PDAC patients from normal individuals, and from individuals with benign pancreatic diseases, exhibiting high specificity without significant non-specific elevation interference. Combined detection with CA199 can synergistically enhance diagnostic efficacy, significantly reducing the rate of missed diagnoses and misdiagnoses. Simultaneously, this biomarker can assess the postoperative tumor resection effect in PDAC patients, predict whether curative resection is achieved, and provide an effective target for postoperative prognostic monitoring.

The present disclosure generally relates to improved methods for preparing glycoconjugates. The method includes conjugating a saccharide to a carrier protein using an acetoxyborohydride-containing reducing mixture prepared in situ.

The present invention discloses novel monoclonal antibodies and functional fragments thereof that specifically bind to SLeA carbohydrate antigen with high specificity and selectivity. The invention further provides compositions comprising the antibodies or fragments thereof as well as uses of the antibodies, fragments and compositions.

The invention relates to the technical field of early gastric cancer screening, and discloses a novel biomarker detection method for early gastric cancer screening, which comprises the following steps: S1, preparation before detection: performing joint detection on pepsinogen, gastritin-17, carcino-embryonic antigen and carbohydrate antigen 72-4, and preparing corresponding detection reagents and standard substances; s2, sample collection: adopting a disposable sterile blood taking needle and a vacuum tube, and extracting 3-5ml of venous blood through sterile operation; s3, sample treatment and storage: separating serum through a centrifugal machine, and after the treatment is completed, putting the sample into a storage device for storage; and S4, detection operation: preheating the detector, and then calibrating the detector by a standard product. In the invention, the pepsinogen, the gastritin-17, the carcino-embryonic antigen and the carbohydrate antigen 72-4 are jointly detected, so that the problem of low accuracy possibly caused by the fact that a marker detection method is mostly adopted in the existing early gastric cancer screening is solved.

The application provides a kit for detecting sialylated carbohydrate antigen KL-6 and a use method and application thereof, and relates to the field of in vitro detection. The kit for detecting sialylated carbohydrate antigen KL-6 provided by the application comprises magnetic beads, KL-6 antibodies, acridinium ester, a magnetic bead storage solution, an acridinium ester storage solution, a sample processing solution, a pre-priming solution and a priming solution. The sample processing solution comprises, in terms of mass fraction, 0.03-0.3% polyoxyethylene fatty acid ester, 0.3-2.0% bovine serum albumin, 0.3-2.0% raffinose, 0.3%-2.0% sodium hydroxide, 0.01-1.5% NaN3 and 0.3-1.5% sodium chloride, the rest is purified water, and the pH is 8-10. The kit can be used for determining sialylated carbohydrate antigen KL-6 in serum, and has high accuracy and strong anti-interference ability.

The invention relates to a sensor based on supramolecular calixarene and a preparation method and application thereof. Comprising calixarene and a fluorescent indicator, and the molar ratio of the calixarene to the fluorescent indicator is 1: (3.5-4.5). The calixarene is tert-butyl calixarene (BFT) or calixarene monoboric acid derivative (BFTPS), and the fluorescent indicator is 6, 7-dihydroxy coumarin. The invention also provides a preparation method of the sensor and application of the sensor in detection of carbohydrate antigens, glycoproteins, cancer cells and serum. The calixarene used in the invention has a unique three-dimensional cavity molecular structure, and can selectively adsorb guest molecules of different sizes. Then calixarene is modified, boric acid derivatization groups are introduced, calixarene mono-boric acid derivatives are used as host molecules, XDS is used as a fluorescent indicator, and the sensor based on the supramolecular calixarene is formed and can be used for detecting biological samples such as carbohydrate antigens, glycoproteins, cancer cells and serum.

Provided are compositions and methods for treating diseases associated with aberrant glycosylation of cell surface molecules and expression of tumor-associated carbohydrate antigens (TACA). Also provided are fusion proteins specific to tumor-associated carbohydrate antigens (TACA) comprising a half-life extender molecule, vectors encoding the TACA-fusion proteins, and recombinant cells comprising the TACA-specific fusion proteins.

This invention belongs to the fields of immunology and molecular biology, specifically relating to a nanobody targeting the sialylated glycan antigen (KL-6) and its applications. The nanobody comprises any one of five sets of complementary determinant regions. This invention also provides a nucleic acid molecule encoding the nanobody, a carrier and host cell containing the nucleic acid molecule, a fusion protein and conjugate containing the nanobody, and a pharmaceutical composition containing the above substances. The nanobody of this invention exhibits high specificity and affinity, and can be used to prepare KL-6 detection reagents, in vivo imaging probes, or therapeutic products, particularly showing broad application prospects in the diagnosis and treatment of KL-6-related diseases such as interstitial lung disease.

The present invention discloses a disialoganglioside GD2 affinity peptide and its applications. The affinity peptide YQAF-X sequence is: COOH-Tyr-Gly-Tyr-His-X1-X2-Arg-NH2. Gangliosides are overexpressed in human tumors such as lung cancer, brain cancer, melanoma, etc., and have an impact on the EGFR signaling pathway. GANGLIOSIDE can be used as a carbohydrate antigen to treat cancer. The YQAF-X series of polypeptides can bind to tumor cells with high expression of GANGLIOSIDE, and in vivo optical imaging and results confirm excellent imaging results for various tumors. The tumor detection reagent and surgical navigation imaging agent prepared based on the YQAF-X series can be better applied to early tumor screening, early tumor diagnosis, and intraoperative navigation of tumor surgery.

The invention discloses a method and system for constructing an early diagnosis model of ovarian cancer based on multi-modal data, and relates to the technical field of methods for constructing the early diagnosis model of ovarian cancer, the method for constructing the early diagnosis model of ovarian cancer based on multi-modal data comprises the following steps: S1, obtaining a sample data set, the sample data set comprises pelvic MRI image data and serum samples; s2, extracting DCE-MRI quantitative parameters and ADC (Analog to Digital Converter) values from the pelvic MRI image data; s3, detecting the levels of human epididymal protein 4 and carbohydrate antigen 125 in the serum sample; s4, taking the DCE-MRI quantitative parameters, the ADC value, the serum human epididymal protein 4 level and the carbohydrate antigen 125 level as input characteristics, and constructing an ovarian cancer early diagnosis model; through pelvic MRI image data and serum sample data, an accurate and effective early diagnosis model of ovarian cancer is constructed, the sensitivity and specificity of early diagnosis of ovarian cancer are improved, and a reliable basis is provided for clinical diagnosis.

The invention belongs to the technical field of immunoassay and biosensing, and provides a preparation method and application of an electrochemiluminescence sensor based on a self-luminous europium-based metal organic framework. A europium-based metal organic framework is adopted as an electrogenerated chemiluminescence material, and an organic ligand 2, 6-dipicolinic acid utilizes an antenna effect to improve an intramolecular energy transfer path, so that europium ions are efficiently sensitized, and a high-strength electrogenerated chemiluminescence signal is obtained. Nitrogen-doped carbon-coated copper-cobalt alloy balls are adopted as a co-reaction accelerant, on one hand, a high-conductivity nitrogen-doped carbon layer can improve the migration rate of charges, on the other hand, a copper-cobalt bimetallic catalyst active center can promote generation of more strong-oxidizing-property triethylamine free radicals, and the luminous efficiency of the europium-based covalent organic framework is further improved. A layer-by-layer self-assembly technology is utilized to construct a signal enhanced electrochemiluminescence sensor, and sensitive and rapid detection of carbohydrate antigen 724 is realized.

The present invention relates to the field of modified proteins, immunogenic compositions and vaccines comprising said modified proteins, their preparation and the use of such compositions in medicine. More specifically, the present invention relates to a modified Als 3 (Candida albicans lectin-like sequence 3) protein. The modified Als3 protein can be used as a carrier protein for other antigens, especially carbohydrate antigens or other antigens lacking T cell epitopes.

Novel glycoconjugates as vaccines and diagnostic tools are described herein. The novel glycoconjugates are produced by conjugating carbohydrate antigen intermediates to free amine groups of a carrier material (e.g., a carrier protein). The intermediate comprises a linker having a first end and a second end, the first end being conjugated to a carbohydrate antigen via a thioether bond, and the second end comprising a functional group capable of reacting with a free amine group. Upon coupling, the carbohydrate antigen is covalently bound to the carrier material via an amide, carbamate, sulfamoyl, urea or thiourea bond to produce a new glycoconjugate. The use of the novel glycoconjugates as antigens, immunogens, vaccines and in diagnostics is also described. In particular, the use of (novel) glycoconjugates as vaccine candidates and other therapeutic tools to combat cancers, viruses such as SARS-CoV-2 and other diseases characterized by aberrant glycosylation expression is also described.

The application relates to the technical field of immunosensors, in particular to a Gd MOF composite material, an immunosensor and a preparation method and application thereof. The preparation method of the Gd MOF composite material comprises the following steps: dissolving polyether F127 in a mixed solvent, then adding gadolinium (Gd) salt and 5-aminoisophthalic acid (5-AIPA) to carry out a first heating reaction to obtain Gd MOF; dispersing the Gd MOF in a copper salt solution to carry out a second heating reaction to obtain the Gd MOF composite material. The application further provides a double-ligand Gd MOF composite material prepared by the method, a luminescent body combined with an antibody, an immunosensor and a preparation method. The application provides a novel MOF material, and the MOF material is used in an ECL sensing system, so that efficient detection of carbohydrate antigen 19-9 (CA19-9) is realized.

The application discloses an antibody against carbohydrate antigen 199 and application thereof, and relates to the field of antibodies. The antibody against carbohydrate antigen 199 disclosed by the application comprises a heavy chain complementarity determining region and a light chain complementarity determining region, the antibody provides an important raw material source for detection of carbohydrate antigen 199, and has good activity.

The utility model discloses an antigen dilution assisting and temporary storage device which comprises a box body, a plurality of supporting pieces are correspondingly arranged on the inner wall of the box body, a placing plate is mounted on the supporting pieces, and a plurality of groups of through holes for inserting antigen test tubes are formed in the placing plate; dilution volume values corresponding to the through holes in each transverse row are engraved on the top surface of the placing plate, and dilution concentration values corresponding to the through holes in each longitudinal row are engraved on the top surface of the placing plate; the box body located below the placing plate is filled with cooling liquid, and cooling assemblies used for cooling the cooling liquid are installed on the two sides of the box body. According to the device, the risk of misoperation in the dilution process of the carbohydrate antigen C199 sample can be reduced, and meanwhile, the activity of the sample can be ensured in the experiment process, so that a relatively perfect detection result can be obtained.

Disclosed herein is a glycoengineered tumor cell or a glycoengineered tumor cell fragment for use in treatment and / or prevention of cancer, in particular cancerous neoplasms, in a subject. The glycoengineered tumor cell or tumor cell fragment includes a tumor cell surface including one or more carbohydrate antigen moieties. Furthermore, a pharmaceutical composition including such a cell or cell fragment, a method for producing such a glycoengineered tumor cell or tumor cell fragment and a method of treatment of a subject including the administration of such a glycoengineered tumor cell or glycoengineered tumor cell fragment to a subject is disclosed.

The present invention pertains to humanized anti-Lewis Y antibodies which specifically bind to Lewis Y and do not show any cross-reactivity. Especially, the humanized anti-Lewis Y antibodies do not bind to Lewis b or any other blood group carbohydrate antigen. In particular, the present invention is directed to humanized anti-Lewis Y antibodies which are useful in the treatment of cancer.

The present invention relates to the field of modified proteins, immunogenic compositions and vaccines comprising said modified proteins, their preparation and the use of such compositions in medicine. More specifically, the present invention relates to a modified Sap2 (Secretory Aspartic Protease 2 of Candida albicans) protein. The modified Sap2 protein can be used as other antigens, in particular as a carrier protein for carbohydrate antigens or other antigens lacking T cell epitopes.

Provided herein is an enzyme for carbohydrate B-antigen cleavage, methods, uses, apparatuses and systems associated therewith. In particular, the enzyme comprises an alpha-galactosidase and may further comprise a crowding agent. Furthermore, the enzymes described herein were found to have activity a temperatures and pH levels suitable for cell viability.